Navigation Links
Aspirin May Protect Against Colorectal Cancer -- But Only in Certain People
Date:3/11/2011

FRIDAY, March 11 (HealthDay News) -- Taking aspirin to protect against colorectal cancer may be effective, but mostly in people at increased risk for the disease due to elevated levels of an inflammatory biomarker in their blood, according to a new study.

Previous research has found that people who take aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) have a reduced risk of colorectal cancer. Other studies have noted that inflammation contributes to the development of conditions such as cardiovascular disease and several types of cancer.

In this new study, researchers at Massachusetts General Hospital and the Dana-Farber Cancer Institute found that elevated baseline levels of an inflammatory marker called "soluble tumor necrosis factor receptor-2 (sTNFR-2)" were associated with increased risk of colorectal cancer and also predicted who might benefit from taking aspirin or other NSAIDs, such as ibuprofen or naproxen.

The researchers analyzed data from 280 participants in the Nurses' Health Study who were cancer-free when they provided a blood sample in 1989 and 1990, but developed colorectal cancer over the next 14 years. These patients were compared to 555 age-matched participants who did not develop colorectal cancer.

The researchers analyzed baseline levels of three inflammatory markers -- sTNFR-2, c-reactive protein (CRP), and interleukin-6 (IL-6). There was no association between levels of CRP or IL-6 and risk of developing colorectal cancer. But people with the highest levels of sTNFR-2 were 60 percent more likely to develop colorectal cancer than those with the lowest levels of the factor.

The researchers also found that the reduced risk of colorectal cancer associated with regular use of aspirin or other NSAIDs was primarily seen among people with high baseline levels of sTNFR-2.

The study appears in the March issue of the journal Gastroenterology.

"These findings suggest that a blood biomarker may be helpful in deciding whether individuals should take aspirin or NSAIDs to reduce their cancer risk," lead author Dr. Andrew Chan, of the gastrointestinal unit at Massachusetts General Hospital, said in a hospital news release.

"They also indicate that chronic inflammatory pathways are quite complex, and further studies are needed to understand which facets of the inflammatory response are most associated with the development of colorectal cancer," he added.

More information

The U.S. National Cancer Institute has more about colorectal cancer prevention.

-- Robert Preidt

SOURCE: Massachusetts General Hospital, Dana-Farber Cancer Institute, news release, March 9, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Aspirins ability to protect against colorectal cancer may depend on inflammatory pathways
2. Small bowel blood flow in healthy subjects receiving low-dose aspirin
3. Low-Dose Aspirin Boosts Accuracy of Colon Cancer Test
4. Low-dose aspirin reduces death rates from range of cancers by between 20 and 30 percent
5. Daily Aspirin Linked to Steep Drop in Cancer Risk
6. Bleeding Risk With Plavix-Aspirin Regimen May Be Serious
7. Aspirin May Help Patients Beat Prostate Cancer
8. Aspirin, Statins May Reduce Problems After Heart Surgery
9. IV Aspirin Drip Appears to Be Safe, Effective for Migraine
10. Low-Dose Aspirin May Reduce Colon Cancer Risk
11. Can aspirin prolong a healthy life?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Aspirin May Protect Against Colorectal Cancer -- But Only in Certain People
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER TOLEDO has ... personnel have a basic understanding of the techniques they use so they can ... help them reduce waste and rework to create a leaner overall lab experience. ...
(Date:2/9/2016)... ... 09, 2016 , ... United Methodist Communications collaborated with Chocolate ... animated video designed to prevent the next widespread Ebola outbreak from ... being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and other African ...
(Date:2/9/2016)... ... 09, 2016 , ... Shark Finds and Kevin Harrington, and the Product Managers of ... GRIP-DRY is a newly patented product that has solved some of the basic problems golfers ... early morning dew or right after a rain shower, might understand the struggle of placing ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Federal ... federallabs.org . The site houses a wealth of federal resources that businesses ... the process called technology transfer (T2). As a network of over 300 federal ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... Houma, LA, celebrates the beginning of a new charity campaign. As part of ... Appointed Special Advocates (CASA). In the belief that children deserve a voice, and ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 9, 2016 Mast Therapeutics, Inc. (NYSE ... sickle cell disease and heart failure, today announced that it ... purchase common stock in an underwritten public offering.  The offering ... be no assurance as to whether or when the offering ... terms of the offering.   --> ...
(Date:2/9/2016)... Feb. 9, 2016 The new report "Global Diagnostic Ultrasound ... & Consulting group reveals that global diagnostic ultrasound devices market was ... to US$ 7,466.3 million by 2019 at a CAGR of 6.8% ... global ultrasound market has been analyzed for six geographies of ... Asia-Pacific , Latin America , ...
(Date:2/9/2016)... , Feb. 9, 2016 The leader ... that AcceleDent ® is the recipient of the ... category. An FDA-cleared, Class II medical device that speeds ... percent and relieves pain often associated with treatment, AcceleDent ... participated in the annual Orthotown survey of ...
Breaking Medicine Technology: